HDL-cholesterol and abdominal circumference: could be predictors of metabolic syndrome in treatment with atypical antipsychotics?

Poster B72, Friday, October 21, 11:30 am - 1:00 pm, Le Baron

Clara Franch1, Gema Medina2, Elena Calzada1, Aranzazu Ugidos1, Rocio Gómez1; 1Complejo Asistencial Universitario de León, 2Hospital Clínico Universitario de Valladolid

Introduction: Schizophrenia and other psychotic disorders are associated with high morbidity and mortality causes, due to inherent health factors, genetic factors and factors related to psychopharmacological treatment. Antipsychotics, like other drugs, have side effects that can substantially affect the physical health of patients, with substantive differences in the side effects profile and in patients in which these effects occur. To understand and identify these risk groups could help to prevent the occurrence of the undesired effects. Material and Methods: Prospective study, with 24 months follow-up, to analyze the physical health of severe mental patients under maintenance treatment with atypical antipsychotics in order to verify the existence of predictive parameters at anthropometric and/or analytical level for good/bad evolution of metabolic syndrome in these patients. Results: There were no significant changes in the physical and biochemical parameters individually analyzed throughout the different visits. The basal abdominal circumference (Lamba Wilks p=0.013) and HDL-basal cholesterol levels (Lamba Wilks p=0.000) are the parameters that seem to be more relevant above the rest of the metabolic syndrome constituents diagnosed criteria, as predictors in the long-term. Conclusions: In the search for predictive factors of metabolic syndrome, HDL-cholesterol and abdominal circumference were selected at the moment of the inclusion, so that the worse baseline results were, the higher probability of long-term improvement.

Topic Area: Psychopharmacology

Back to Poster Schedule